ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent?
Overview
NA
Target Audience
NA
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Sai-Hong Ignatius Ou, MD, PhD
Date of Release
May 14th, 2025
